0
Miragen Therapeutics, Inc. Banner Image

Miragen Therapeutics, Inc. has reached its limit for free report views

Work for Miragen Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Miragen Therapeutics, Inc.

  • Ticker MGEN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Miragen Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Boulder, Colorado
miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen, remlarsen, and MRG-110. miRagen’s clinical product candidate for the treatment of certainMore cancers, cobomarsen, is an inhibitor of miR-155, which is found at abnormally high levels in malignant cells of several blood cancers. miRagen’s clinical product candidate for the treatment of pathological fibrosis, remlarsen, is a replacement for miR-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as in systemic sclerosis. MRG-110, an inhibitor of miR-92, is miRagen’s product candidate for the treatment of heart failure and other ischemic disease. In addition to these programs, miRagen is developing a pipeline of preclinical product candidates.
Miragen Therapeutics, Inc.

Most Recent Annual Report

Miragen Therapeutics, Inc. MOST RECENT 2019 Form 10K

Report Locked. Miragen Therapeutics, Inc. has reached its limit for free report views.